Co-Authors
This is a "connection" page, showing publications co-authored by MICHAEL A DAVIES and EDMUND SCOTT KOPETZ.
Connection Strength
0.813
-
Overcoming resistance to MAPK pathway inhibitors. J Natl Cancer Inst. 2013 Jan 02; 105(1):9-10.
Score: 0.450
-
Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res. 2014 Nov 01; 20(21):5537-46.
Score: 0.124
-
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res. 2013 Feb 01; 19(3):657-67.
Score: 0.112
-
A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
Score: 0.033
-
Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2644-51.
Score: 0.033
-
Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin Chem. 2015 Mar; 61(3):544-53.
Score: 0.033
-
Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome. PLoS One. 2013; 8(6):e65144.
Score: 0.029